Massive Spontaneous Haemothorax after Rivaroxaban Therapy for Acute Pulmonary Embolism by Tan, Yan Denise et al.
European Journal
of Case Reports in
Internal Medicine
DOI: 10.12890/2019_001236 European Journal of Case Reports in Internal Medicine © EFIM 2019
Doi: 10.12890/2019_001236- European Journal of Case Reports in Internal Medicine - © EFIM 2019
 
Massive Spontaneous Haemothorax after Rivaroxaban Therapy 
for Acute Pulmonary Embolism 
Denise Tan Yan1,2, Raymond Goh Kai Heng1, Heng Joo Ng2  
1Department of Medicine, Sengkang General Hospital, Singhealth, Singapore
2Department of Haematology, Singapore General Hospital, Singhealth, Singapore
Received: 26/07/2019
Accepted: 31/07/2019
Published: 18/09/2019
How to cite this article: Tan YD, Goh KHR, Ng HJ. Massive spontaneous haemothorax after rivaroxaban therapy for acute pulmonary embolism. EJCRIM 
2019;6: doi:10.12890/2019_001236.
Conflicts of Interests: The Authors declare that there are no competing interest 
This article is licensed under a Commons Attribution Non-Commercial 4.0 License
ABSTRACT
Spontaneous haemothorax complicating the treatment of pulmonary embolism is rare and potentially fatal. We describe a patient with 
pulmonary embolism and severe pleuritic pain who developed a life-threatening haemothorax 10 days later while on rivaroxaban therapy. 
This case highlights the fact that severe pleuritic pain associated with pulmonary embolism may indicate subclinical infarction of tissue near 
the visceral pleura with an increased risk of pleural effusion and the subsequent development of a haemothorax. It is important to recognise 
such danger signs warranting closer attention, especially since the increased use of direct oral anticoagulants has facilitated ambulatory 
care and this complication may manifest in the outpatient setting.
LEARNING POINTS
•	 Spontaneous	haemothorax	may	occur	in	the	first	2	weeks	after	a	patient	starts	anticoagulation.
• Severe pleuritic pain in a patient with pulmonary embolism may indicate subclinical infarction near the visceral pleura with an increased 
risk of pleural effusion and the subsequent development of a spontaneous haemothorax. 
• Patients with severe pain and pleural effusion should be monitored closely, especially if they are outpatients, even though initial 
radiological	findings	are	not	significant.	
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INTRODUCTION
Massive spontaneous haemothorax complicating the treatment of pulmonary embolism is rare and potentially fatal. It is caused by the 
rupture of small blood vessels, often in the presence of a pulmonary infarct[1]. Severe pleuritic pain, especially with associated pleural 
effusion, suggests subpleural ischaemia or infarction which may not always be radiologically detectable. 
Here we describe a patient with pulmonary embolism and severe pleuritic pain who subsequently developed a life-threatening spontaneous 
haemothorax on rivaroxaban therapy.
CASE DESCRIPTION
A 24-year old man presented with a 1-day history of severe left-sided pleuritic chest pain after 8 weeks of immobilisation of his right foot 
for	a	metatarsal	fracture.	His	was	febrile	with	a	temperature	of	38.6°C	but	vital	signs	were	stable.	He	had	no	significant	medical	or	bleeding	
history. 
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His	blood	counts,	coagulation	profile	and	chest	x-ray	(CXR)	were	normal	(Fig. 1).	A	computed	tomography	pulmonary	angiogram	(CTPA)	
showed pulmonary embolism involving bilateral lower lobe segmental arteries and their branches with a small left-sided pleural effusion, 
but	without	the	typical	features	of	a	pulmonary	infarct	(Fig. 2).
Figure 1. Chest x-ray at first presentation Figure 2. CT pulmonary angiogram showing bilateral lower lobe segmental artery thrombosis
Enoxaparin at 1 mg/kg administered every 12 hours was initiated. It was unusual that his pain was out of proportion to the radiological 
findings	and	was	difficult	to	control,	even	with	regular	morphine.	He	was	clinically	monitored	for	5	more	days	until	his	pain	improved,	then	
discharged	with	oral	opioids	and	rivaroxaban	15	mg	twice	daily.
The	patient	returned	5	days	later	with	worsening	pleuritic	chest	pain	and	dyspnoea	that	began	2	days	after	discharge.	A	CXR	now	showed	
a	moderate-sized	left	pleural	effusion	(Fig. 3).	His	vital	signs	were	initially	normal	but	he	developed	haemodynamic	shock	within	12	hours	
of	 presentation.	Urgent	CXR	 after	 fluid	 resuscitation	 showed	 progression	 into	 a	massive	 effusion	with	mediastinal	 shift	 (Fig. 4).	 CTPA	
did	not	show	any	new	pulmonary	embolisms	but	confirmed	a	 large	pleural	effusion	with	dependent	hyperdense	contents	suspicious	for	
haemorrhage	and	passive	collapse	of	the	left	lung	with	a	rightward	mediastinal	shift	(Fig. 5).
Figure 3. Chest x-ray showing a moderate-sized left pleural effusion Figure 4. Chest x-ray showing a massive left pleural effusion with mediastinal shift
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Figure 5. Computed tomography pulmonary angiogram showing a massive 
left haemothorax with collapse of the left lung
Rivaroxaban	was	 stopped	 and	 four-factor	 prothrombin	 complex	 concentrate	 at	 50	 IU/kg	was	 administered.	A	 chest	 tube	was	 inserted	
and	immediately	drained	2	litres	of	frank	blood.	The	patient’s	haemoglobin	dropped	from	a	baseline	of	14.0	g/dl	during	the	first	admission	
to 7.4 g/dl. Video-assisted thoracoscopy was considered but not performed as there was no evidence of further bleeding. The chest tube 
was	removed	when	there	was	no	more	drainage	and	the	patient	was	followed	up	with	repeat	CXRs	to	ensure	no	further	recurrence	of	the	
haemothorax. 
DISCUSSION
This patient had pulmonary embolism with symptoms of severe pleuritis, but there was no obvious radiological evidence of pulmonary 
infarction on initial imaging. Pleuritic pain is a common symptom in patients with pulmonary embolism and associated pleural effusion[2]. 
As with this patient, they are managed according to standard of care and anticoagulation is not contraindicated[2]. Apart from clinical 
assessments, such pleural effusions are usually not monitored radiologically. 
Pleural effusion secondary to pulmonary embolism may be further complicated by the development of haemothorax. This secondary 
event can occur 1–2 weeks after the patient starts anticoagulation[3, 4]. This timing corresponds to a period of maximum tissue necrosis and 
breakdown after an infarction. The rupture of infarcted tissue and blood vessels near the visceral pleura can cause rapid accumulation of 
blood	in	the	pleural	cavity.	Case	reports	of	fatalities	with	post-mortem	findings	have	demonstrated	this	phenomenon[4,	5].
Bleeding	is	further	accentuated	by	the	use	of	anticoagulants.	Although	this	is	the	first	report	of	spontaneous	haemothorax	with	rivaroxaban,	
the	few	available	publications	mentioning	other	anticoagulants	suggest	it	is	not	exclusive	to	any	specific	class	of	anticoagulant[5,	6].
This	 case	 highlights	 the	 fact	 that	 significant	 pleuritic	 pain	 in	 a	 patient	with	 pulmonary	 embolism	may	 indicate	 ischaemia	 or	 subclinical	
infarction of tissue near the visceral pleura with an increased risk of pleural effusion and the subsequent development of a haemothorax. 
Such patients should be considered for closer monitoring and additional reassessment such as early repeat imaging. Especially since the 
increased use of direct oral anticoagulants has facilitated ambulatory care and shorter duration of hospitalisation, pulmonary embolism 
patients and their physicians should be more aware of this complication which may manifest in the outpatient setting. Patients should also 
be	adequately	warned	of	danger	signals	such	as	recurrence	of	pain	or	dyspnoea	in	the	first	2	weeks	after	diagnosis.
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